PPARα ligands cause lymphocyte depletion and cell cycle block and this is associated with augmented TRB3 and reduced Cyclin B1 expression

Molecular Immunology

Volumn 46, Issue 16, 2009, Pages 3454-3461

  Morse, Elizabeth ^a   Selim, Erin ^a   Cunard, Robyn ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cell cycle block; Cyclin B1; Fibrates; PPAR ; TRB3

Indexed keywords

CELL PROTEIN; CYCLIN B1; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA LIGAND; PHOSPHOTRANSFERASE; PIRINIXIC ACID; PROTEIN CDC25C; PROTEIN KINASE B; TRIBBLE 3 PROTEIN; UNCLASSIFIED DRUG; CDC25C PROTEIN, MOUSE; CELL CYCLE PROTEIN; CYCLIN B; LIGAND; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN TYROSINE PHOSPHATASE; PYRIMIDINE DERIVATIVE; TRB3 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; IMMUNOMODULATION; INHIBITION KINETICS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECT; DRUG POTENTIATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PHOSPHORYLATION; PROMOTER REGION; UPREGULATION;

ANIMALS; CDC25 PHOSPHATASES; CELL CYCLE PROTEINS; CELL SURVIVAL; CYCLIN B; G2 PHASE; HUMANS; LIGANDS; LYMPHOCYTE DEPLETION; LYMPHOCYTES; MICE; MICE, INBRED BALB C; PEROXISOME PROLIFERATORS; PHOSPHORYLATION; PPAR ALPHA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; S PHASE; UP-REGULATION;

EID: 70349451948     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.08.008     Document Type: Article

References (71)

1. Atarod E.B., and Kehrer J.P. Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines. Free Radic. Biol. Med. 37 (2004) 36-47
2. Bowers A.J., Scully S., and Boylan J.F. SKIP3, a novel Drosophila tribbles ortholog, is overexpressed in human tumors and is regulated by hypoxia. Oncogene 22 (2003) 2823-2835
3. Cantrell D. Protein kinase B (Akt) regulation and function in T lymphocytes. Semin. Immunol. 14 (2002) 19-26
4. Chapman D.L., and Wolgemuth D.J. Identification of a mouse B-type cyclin which exhibits developmentally regulated expression in the germ line. Mol. Reprod. Dev. 33 (1992) 259-269
5. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171 (2003) 1-13
6. Cogswell J.P., Godlevski M.M., Bonham M., Bisi J., and Babiss L. Upstream stimulatory factor regulates expression of the cell cycle-dependent cyclin B1 gene promoter. Mol. Cell. Biol. 15 (1995) 2782-2790
7. Cunard R. The potential use of PPARalpha agonists as immunosuppressive agents. Curr. Opin. Investig. Drugs 6 (2005) 467-472
8. Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., and Kelly C.J. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J. Immunol. 169 (2002) 6806-6812
9. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., and Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 168 (2002) 2795-2802
10. Du K., Herzig S., Kulkarni R.N., and Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300 (2003) 1574-1577
11. Duez H., Chao Y.S., Hernandez M., Torpier G., Poulain P., Mundt S., Mallat Z., Teissier E., Burton C.A., Tedgui A., Fruchart J.C., Fievet C., Wright S.D., and Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem. 277 (2002) 48051-48057
12. Duez H., Fruchart J.C., and Staels B. PPARS in inflammation, atherosclerosis and thrombosis. J. Cardiovasc. Risk 8 (2001) 187-194
13. Ericsson C.G., Hamsten A., Nilsson J., Grip L., Svane B., and de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
14. Foe V., Odell G., and Edgar B. Mitosis and morphogenesis in the Drosophila embryo: point and counterpoint. In: Bate M., and Martinez Arias A. (Eds). The Development of Drosophila melanogaster vol. 1 (1993), Cold Spring Harbor Laboratory Press, New York 425-465
15. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317 (1987) 1237-1245
16. Frick M.H., Syvanne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., Kesaniemi Y.A., Pasternack A., and Taskinen M.R. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96 (1997) 2137-2143
17. Grosshans J., and Wieschaus E. A genetic link between morphogenesis and cell division during formation of the ventral furrow in Drosophila. Cell 101 (2000) 523-531
18. Hanada M., Feng J., and Hemmings B.A. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim. Biophys. Acta 1697 (2004) 3-16
19. Hanks S.K., and Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9 (1995) 576-596
20. He L., Simmen F.A., Mehendale H.M., Ronis M.J., and Badger T.M. Chronic ethanol intake impairs insulin signaling in rats by disrupting Akt association with the cell membrane. Role of TRB3 in inhibition of Akt/protein kinase B activation. J. Biol. Chem. 281 (2006) 11126-11134
21. Hwang A., Maity A., McKenna W.G., and Muschel R.J. Cell cycle-dependent regulation of the cyclin B1 promoter. J. Biol. Chem. 270 (1995) 28419-28424
22. Innocente S.A., Abrahamson J.L., Cogswell J.P., and Lee J.M. p53 regulates a G2 checkpoint through cyclin B1. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 2147-2152
23. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
24. Iynedjian P.B. Lack of evidence for a role of TRB3/NIPK as an inhibitor of PKB-mediated insulin signalling in primary hepatocytes. Biochem. J. 386 (2005) 113-118
25. Jiao H.L., and Zhao B.L. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol. Appl. Pharmacol. 185 (2002) 172-179
26. Jonkers I.J., Mohrschladt M.F., Westendorp R.G., van der Laarse A., and Smelt A.H. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am. J. Med. 112 (2002) 275-280
27. Kane L.P., and Weiss A. The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol. Rev. 192 (2003) 7-20
28. Kao G.D., McKenna W.G., Maity A., Blank K., and Muschel R.J. Cyclin B1 availability is a rate-limiting component of the radiation-induced G2 delay in HeLa cells. Cancer Res. 57 (1997) 753-758
29. Kato S., and Du K. TRB3 modulates C2C12 differentiation by interfering with Akt activation. Biochem. Biophys. Res. Commun. 353 (2007) 933-938
30. Kiss-Toth E., Bagstaff S.M., Sung H.Y., Jozsa V., Dempsey C., Caunt J.C., Oxley K.M., Wyllie D.H., Polgar T., Harte M., O'Neill L.A., Qwarnstrom E.E., and Dower S.K. Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J. Biol. Chem. 279 (2004) 42703-42708
31. Kleemann R., Gervois P.P., Verschuren L., Staels B., Princen H.M., and Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101 (2003) 545-551
32. Kleemann R., Verschuren L., de Rooij B.J., Lindeman J., de Maat M.M., Szalai A.J., Princen H.M., and Kooistra T. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103 (2004) 4188-4194
33. Lalwani N.D., Dethloff L.A., Haskins J.R., Robertson D.G., and de la Iglesia F.A. Increased nuclear ploidy, not cell proliferation, is sustained in the peroxisome proliferator-treated rat liver. Toxicol. Pathol. 25 (1997) 165-176
34. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., Valledor A.F., Davis R.A., Willson T.M., Witztum J.L., Palinski W., and Glass C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114 (2004) 1564-1576
35. Ma X., Stoffregen D.A., Wheelock G.D., Rininger J.A., and Babish J.G. Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21Waf1 cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) dosing to rats. Mol. Pharmacol. 51 (1997) 69-78
36. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., Kalina Z., and Herman Z.S. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int. J. Clin. Pharmacol. Ther. 36 (1998) 345-349
37. Malik J., Melenovsky V., Wichterle D., Haas T., Simek J., Ceska R., and Hradec J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc. Res. 52 (2001) 290-298
38. Malstrom S., Tili E., Kappes D., Ceci J.D., and Tsichlis P.N. Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 14967-14972
39. Manni I., Mazzaro G., Gurtner A., Mantovani R., Haugwitz U., Krause K., Engeland K., Sacchi A., Soddu S., and Piaggio G. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J. Biol. Chem. 276 (2001) 5570-5576
40. Mata J., Curado S., Ephrussi A., and Rorth P. Tribbles coordinates mitosis and morphogenesis in Drosophila by regulating string/CDC25 proteolysis. Cell 101 (2000) 511-522
41. Matsushima R., Harada N., Webster N.J., Tsutsumi Y.M., and Nakaya Y. Effect of TRB3 on insulin and nutrient-stimulated hepatic p70 S6 kinase activity. J. Biol. Chem. 281 (2006) 29719-29729
42. Mayumi-Matsuda K., Kojima S., Suzuki H., and Sakata T. Identification of a novel kinase-like gene induced during neuronal cell death. Biochem. Biophys. Res. Commun. 258 (1999) 260-264
43. Millar J.B., Blevitt J., Gerace L., Sadhu K., Featherstone C., and Russell P. p55CDC25 is a nuclear protein required for the initiation of mitosis in human cells. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 10500-10504
44. Millar J.B., and Russell P. The cdc25 M-phase inducer: an unconventional protein phosphatase. Cell 68 (1992) 407-410
45. Moreno S., Nurse P., and Russell P. Regulation of mitosis by cyclic accumulation of p80cdc25 mitotic inducer in fission yeast. Nature 344 (1990) 549-552
46. Murray A.W., Solomon M.J., and Kirschner M.W. The role of cyclin synthesis and degradation in the control of maturation promoting factor activity. Nature 339 (1989) 280-286
47. Ohoka N., Yoshii S., Hattori T., Onozaki K., and Hayashi H. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J. 24 (2005) 1243-1255
48. Panaretakis T., Shabalina I.G., Grander D., Shoshan M.C., and DePierre J.W. Reactive oxygen species and mitochondria mediate the induction of apoptosis in human hepatoma HepG2 cells by the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid. Toxicol. Appl. Pharmacol. 173 (2001) 56-64
49. Pines J., and Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 58 (1989) 833-846
50. Rizos E., Kostoula A., Elisaf M., and Mikhailidis D.P. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 53 (2002) 273-277
51. Roberts R.A., Chevalier S., Hasmall S.C., James N.H., Cosulich S.C., and Macdonald N. PPAR alpha and the regulation of cell division and apoptosis. Toxicology 181-182 (2002) 167-170
52. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., McNamara J.R., Kashyap M.L., Hershman J.M., Wexler L.F., and Rubins H.B. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
53. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
54. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., and Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341 (1999) 410-418
55. Russell P., and Nurse P. cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 45 (1986) 145-153
56. Saitoh K., Mori T., Kasai H., Nagayama T., and Ohbayashi S. Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. II. Anti-atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits. Nippon Yakurigaku Zasshi 106 (1995) 51-60
57. Salazar M., Carracedo A., Salanueva I.J., Hernandez-Tiedra S., Lorente M., Egia A., Vazquez P., Blazquez C., Torres S., Garcia S., Nowak J., Fimia G.M., Piacentini M., Cecconi F., Pandolfi P.P., Gonzalez-Feria L., Iovanna J.L., Guzman M., Boya P., and Velasco G. Cannabinoid action induces autophagymediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 119 (2009) 1359-1372
58. Seher T.C., and Leptin M. Tribbles, a cell-cycle brake that coordinates proliferation and morphogenesis during Drosophila gastrulation. Curr. Biol. 10 (2000) 623-629
59. Selim E., Frkanec J.T., and Cunard R. Fibrates upregulate TRB3 in lymphocytes independent of PPAR alpha by augmenting CCAAT/enhancer-binding protein beta (C/EBP beta) expression. Mol. Immunol. 44 (2007) 1218-1229
60. Shang Y.Y., Wang Z.H., Zhang L.P., Zhong M., Zhang Y., Deng J.T., and Zhang W. TRB3, upregulated by ox-LDL, mediates human monocyte-derived macrophage apoptosis. FEBS J. 276 (2009) 2752-2761
61. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (1998) 790-793
62. Strausfeld U., Labbe J.C., Fesquet D., Cavadore J.C., Picard A., Sadhu K., Russell P., and Doree M. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351 (1991) 242-245
63. Tang K., Finley Jr. R.L., Nie D., and Honn K.V. Identification of 12-lipoxygenase interaction with cellular proteins by yeast two-hybrid screening. Biochemistry 39 (2000) 3185-3191
64. Trama J., Lu Q., Hawley R.G., and Ho S.N. The NFAT-related protein NFATL1 (TonEBP/NFAT5) is induced upon T cell activation in a calcineurin-dependent manner. J. Immunol. 165 (2000) 4884-4894
65. Wilkin F., Suarez-Huerta N., Robaye B., Peetermans J., Libert F., Dumont J.E., and Maenhaut C. Characterization of a phosphoprotein whose mRNA is regulated by the mitogenic pathways in dog thyroid cells. Eur. J. Biochem. 248 (1997) 660-668
66. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-II10
67. Wu H., Moulton K., Horvai A., Parik S., and Glass C.K. Combinatorial interactions between AP-1 and ets domain proteins contribute to the developmental regulation of the macrophage scavenger receptor gene. Mol. Cell. Biol. 14 (1994) 2129-2139
68. Wu M., Xu L.G., Zhai Z., and Shu H.B. SINK is a p65-interacting negative regulator of NF-kappaB-dependent transcription. J. Biol. Chem. 278 (2003) 27072-27079
69. Yang Q., Abedi-Valugerdi M., Xie Y., Zhao X.Y., Moller G., Nelson B.D., and DePierre J.W. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2 (2002) 389-397
70. Yang Q., Xie Y., and Depierre J.W. Effects of peroxisome proliferators on the thymus and spleen of mice. Clin. Exp. Immunol. 122 (2000) 219-226
71. Yang Q., Xie Y., Eriksson A.M., Nelson B.D., and DePierre J.W. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. Biochem. Pharmacol. 62 (2001) 1133-1140